Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

Video

Penn Precision Medicine – Accelerator Fund Projects: Niraparib + Immunotherapy for Pancreatic Cancer

Kim A. Reiss Binder, MD, describes a therapeutic approach in Phase 2 clinical trials at the Penn Center for Precision Medicine for patients with pancreatic cancer, for whom the toxicities of platinum-based chemotherapy may complicate or preclude treatment. The therapy under investigation at the PCPM will offer a combination of niraparib, a PARP inhibitor, plus immunotherapy as maintenance therapy for patients whose imaging and genetic sequencing profiles suggests a safe step-down from toxic chemotherapy. Dr. Binder is an Assistant Professor of Medicine at Penn Medicine.

Related Links:
Dr Reiss Binder’s Profile

ADVERTISEMENT

Related Videos